Badalona, Spain – Multiple myeloma is a type of blood cancer that appears mainly after the age of sixty. Its incidence, therefore, increases with the aging of the population. In this pathology, the bone marrow, the porous structure within the bones that produces normal blood cells, is invaded by an...
Latest News
BEDMINSTER, N.J. – Jubilant Therapeutics Inc, a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (FDA) clearance of the investigational new drug application (IND) for JBI-802, a novel, oral, potent and selective dual inhibitor...
A federal appeals court in the U.S. has issued a mandate that effectively vacates the 2019 regulatory approval of Jacobus Pharmaceutical’s Ruzurgi for the treatment of children with Lambert-Eaton myasthenic syndrome (LEMS). The ruling, by the U.S. Court of Appeals for the 11th Circuit, directs a lower district court to...
New York, NY — The Myasthenia Gravis Foundation of America (MGFA) announces its ninth annual “MG Awareness Month” during the month of June, to raise awareness of the often misunderstood and under-diagnosed disease, myasthenia gravis (MG). MG Awareness Month is an effort by MGFA and its local chapters to raise...
SHANGHAI, China — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for the company’s product, toripalimab,...
SHANGHAI, China. — Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the publication of results from the prespecified interim analysis for event-free survival (EFS) in patients with stage III non-Small Cell Lung Cancer (NSCLC) of NEOTORCH (NCT04158440)...
SHANGHAI, China — Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Singapore Health Sciences Authority (HSA) had accepted the New Drug Application (NDA) for toripalimab, both in combination with cisplatin and gemcitabine for the first-line...
Tokyo, Japan – Cervical cancer is among the most common malignancies affecting women worldwide. In 2020 alone, approximately 600,000 women were diagnosed with this disease, and over 314,000 died from it. In 99% of the cases, cervical cancer cells harbor human papilloma virus (HPV), and thus, HPV vaccines are an...
In this multicenter randomized controlled trial, screening uptake of FIT was not different than screening uptake of colonoscopy among FDR with a high-risk family history of non-syndromic CRC. In addition, the detection rate of advanced colorectal neoplasia was significantly higher among subjects undergoing screening colonoscopy than in those receiving FIT...
Moebius Syndrome Foundation organizes this special holiday happy hour for all adults (ages 18+) that have Moebius syndrome. It is a great opportunity to connect with others play some games and get festive! This event is not focused on any one holiday but celebrates all holidays in the month of...